Keynote Speaker

Dr. Jennifer Guerriero is a nationally recognized leader in cancer immunology and breast cancer research. After earning her BSc in Biochemistry from Northeastern University. She completed her PhD in Molecular & Cellular Biology, Immunology and Pathology at Stony Brook University, focusing on innate immunity and cell-death pathways in chemotherapy. She then pursued postdoctoral training at the Dana–Farber Cancer Institute, where she uncovered innovative ways to reprogram tumour-associated macrophages from pro‑tumor to anti‑tumor phenotypes. In 2017, Dr. Guerriero joined Harvard Medical School’s faculty as an Instructor in Medicine, and, in October 2020, she launched her independent laboratory at Brigham and Women’s Hospital.  

Dr. Guerriero is a leader in the field of cancer immunology, with a research program dedicated to understanding and therapeutically targeting tumor-associated macrophages (TAMs) to enhance immunotherapy response. Her laboratory investigates the molecular, phenotypic, and metabolic regulation of myeloid cells within the tumor microenvironment, aiming to reprogram these cells to promote anti-tumor immunity. While her work is grounded in breast cancer, the mechanisms her lab uncovers have broad implications across a variety of solid tumors and immune-driven diseases. 

Beyond her scientific contributions, Dr. Guerriero plays an active role in shaping the field of cancer immunotherapy. She currently serves as Director-at-Large for the Society for Immunotherapy of Cancer (SITC), co-chairs the American Association for Cancer Research (AACR) Cancer Immunology Working Group, and serves on the editorial board of the Journal for ImmunoTherapy of Cancer. She is also the co-founder of The Myeloid Network, a global seminar series dedicated to advancing research on myeloid biology in health and disease. Her work has been published in top-tier journals, including Nature, Cancer Cell, Clinical Cancer Research, and Journal of Immunotherapy of Cancer, and she has led several collaborative efforts exploring macrophage-targeted therapeutics, combination immunotherapies, and mechanisms of immune escape.